Targeted Oncology7h
FDA Grants Breakthrough Therapy Status to Petosemtamab/Pembrolizumab in HNSCC
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
The American Journal of Managed Care3d
2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer
When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 ...
precisionmedicineonline9h
Cel-Sci to Initiate Phase III Trial of Immunotherapy in PD-L1-Low Head and Neck Cancer
The registrational trial will include 212 patients who are newly diagnosed with advanced head and neck cancer.
Nature5y
Unlocking the secrets of PD-L1 signalling
The keys to the lock are immune checkpoints such as programmed cell-death ligand 1 (PD-L1), and its receptor PD-1; discovering this system earned Nobel Prizes for James Allison, at the University ...
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
The Brighterside of News on MSN1d
New AI tool accurately predicts how cancer patients will respond to treatment
Predicting how cancer patients will respond to treatment remains a critical challenge. Immune checkpoint inhibitors (ICIs), a ...
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2024, as well as ...
Medpage Today on MSN5mon
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
He also cautioned that pembrolizumab may not be a relevant comparator for the intermediate PD-L1 population (PD-L1 tumor ...
Pharmabiz17h
Merus’ petosemtamab receives US FDA breakthrough therapy designation for 1L PD-L1 positive head and neck squamous cell carcinoma
Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...